Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Real Brands, Inc. (RLBD)
North Providence, RI, US
Real Brands, Inc. specializes in the comprehensive process of hemp-derived cannabidiol (CBD), from the extraction of CBD oil and isolate, through their wholesale distribution, to the manufacturing and retail of a diverse range of CBD-infused consumer products. Their extensive product line includes topical creams, gels, and lotions, cosmetic items, ingestible options like tinctures, oils, and capsules, as well as vape cartridges and oral sprays. Established in 2011, the company's corporate headquarters are situated in North Providence, Rhode Island.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +900.00% | -90.00% | -98.71% | -99.92% | -99.80% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+443.0% ★ Q1'24: -100.0% (vs Q1'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-66.7% Q1'24: +66.7% (vs Q1'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1,521.1%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-2,112.4%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'24: +130.7% (vs Q1'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.4% Q1'24: 0.0% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.88× Q1'24: -2.30× (vs Q1'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Turning Point Brands, Inc. | 611.26M | 23.20% | 611.26M | — | 611.26M | — | CO | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-24 | Turning Point Brands, Inc. | — | — | D | Common Stock | 0 | 0.00 | — | 611,255,410 | — | ↗ |
| 2021-09-24 | TOBOROFF LEONARD | Director | — | D | Common Stock | 0 | 0.00 | — | 64,721,161 | — | ↗ |
| 2021-09-24 | Ryan Christopher John | Officer | — | D | Common Stock | 0 | 0.00 | — | 165,471,440 | — | ↗ |
| 2021-09-24 | KIDRIN THOMAS | Officer | — | D | Common Stock | 0 | 0.00 | — | 510,937,611 | — | ↗ |
| 2021-09-24 | CHRISTOS PETER N | Director | — | D | Common Stock | 0 | 0.00 | — | 92,946,967 | — | ↗ |
| 2021-05-01 | Dobbins James Wells | Director | — | D | Option to buy common stock | 46,077,210 | 0.03 | 1.23M | 0 | — | ↗ |
| 2020-07-01 | TOBOROFF LEONARD | Director | — | D | Option to buy common stock | 6,143,628 | 0.03 | 164.0K | 0 | — | ↗ |
| 2020-07-01 | CHRISTOS PETER N | Director | — | D | Option to buy common stock | 6,143,628 | 0.03 | 164.0K | 0 | — | ↗ |
| 2008-02-06 | Spitalny Brett S. | Officer | A-Award | A | Common Stock | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2008-02-06 | Silvey Ross E | Director | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2008-02-06 | Pearring Jerry | Director / Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2008-01-02 | Spitalny Brett S. | Officer | A-Award | A | Employee Stock Option (right to buy) | 3,000,000 | 0.01 | 36.0K | 3,000,000 | — | ↗ |
| 2008-01-02 | Pearring Jerry | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 5,000,000 | 0.01 | 60.0K | 5,000,000 | — | ↗ |
| 2007-02-27 | Spitalny Brett S. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-02-23 | Pearring Jerry | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2006-12-31 | Turner Terry J | Director | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2006-12-31 | Silvey Ross E | Director | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-06-21 | MACGREGOR BRUCE | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,321,635 | — | ↗ |
| 2005-06-21 | GURR BERNIE | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,600,000 | — | ↗ |
| 2005-06-07 | WIEDRICH KEN | Director | — | D | Common stock, par value $.001 | 0 | 0.00 | — | 100,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adel Rammal | Chief Scientific Officer | — | — |
| Christopher J. Ryan | Vice President of Finance, Principal Accounting Officer, Chief Financial Officer, Secretary & Treasurer | — | male |
| Thomas Kidrin | Chairman, President & Chief Executive Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RLBD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
